Disease · MONDO_0015909
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants That Remained Disease-free Survival | 26 of 43 | 56 of 57 | 100 | NCT00003838 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Who Experienced Transplant Related Mortality | 5 of 43 | 4 of 57 | 100 | NCT00003838 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Overall Survival | 17 of 43 | 48 of 57 | 100 | NCT00003838 | Trial comparisons |
| Eltrombopag vs Eltrombopag (Post-treatment Long Term Follow-up): deaths from any cause | 1 of 36 | 2 of 34 | 70 | NCT04328727 | Trial comparisons |
| r-ATG /Cyclosporine vs Alemtuzumab (Campath-1H): deaths from any cause | 9 of 27 | 4 of 27 | 54 | NCT00065260 | Trial comparisons |
| r-ATG /Cyclosporine vs Alemtuzumab (Campath-1H): serious adverse events | 7 of 27 | 12 of 27 | 54 | NCT00065260 | Trial comparisons |
| r-ATG /Cyclosporine vs Alemtuzumab (Campath-1H): Number of Participants With Robust Hematologic Recovery With Reticulocyte or Platelet Count | 9 of 27 | 9 of 26 | 53 | NCT00065260 | Trial comparisons |
| Refractory vs Relapsed: Number of Participants With Hematological Response at 6 Months | 0 of 5 | 18 of 42 | 47 | NCT00195624 | Trial comparisons |
| Refractory vs Relapsed: deaths from any cause | 5 of 5 | 13 of 42 | 47 | NCT00195624 | Trial comparisons |
| Refractory vs Relapsed: serious adverse events | 2 of 5 | 22 of 42 | 47 | NCT00195624 | Trial comparisons |
| Eltrombopag (On-treatment) vs Eltrombopag (Post-treatment): deaths from any cause | 0 of 20 | 1 of 20 | 40 | NCT03988608 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Late Secondary Malignancies | 0 of 15 | 4 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Chronic GVHD | 1 of 15 | 2 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) | 1 of 15 | 0 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Chronic GVHD | 0 of 15 | 0 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Pulmonary Complications | 3 of 15 | 3 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Overall Survival | 12 of 15 | 19 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Regimen Related Mortality at 100 Days | 1 of 15 | 2 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD) | 0 of 15 | 0 of 21 | 36 | NCT00455312 | Trial comparisons |
| Patients With DC vs Patients With SAA: Overall Survival | 14 of 15 | 19 of 21 | 36 | NCT00455312 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015909/comparisons